+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889000
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Immunotherapy Drugs Market is projected to reach USD 251.56 Billion in 2026. It is expected to continue growing at a CAGR of 13.61%, reaching USD 543.82 Billion by 2032.

Immunotherapy Drugs: Executive Summary

Immunotherapy drugs activate, restore, or guide immune responses to treat cancer and other serious diseases. The field includes immune checkpoint inhibitors, monoclonal antibodies, cytokine therapies, cellular therapies, cancer vaccines, and immune-modulating agents. Its development is shaped by biomarker science, combination regimens, manufacturing complexity, safety management, and the need to demonstrate durable clinical benefit across diverse patient populations.

Clinical Precision and Delivery Complexity Are Reshaping Immunotherapy

The landscape is shifting from broad immune activation toward biomarker-informed treatment selection and disease-specific immune modulation. Companion diagnostics, molecular profiling, response monitoring, and tissue analysis increasingly support decisions about eligibility and treatment sequencing. At the same time, cell and gene-based approaches introduce specialized collection, processing, logistics, and quality requirements, while conventional biologics continue to face challenges related to administration, immunogenicity, resistance, and immune-related adverse events.

Artificial Intelligence Strengthens Discovery, Diagnosis, and Treatment Decisions

Artificial intelligence can accelerate target identification, antibody and protein design, biomarker discovery, pathology interpretation, and clinical-trial recruitment. It may also help integrate imaging, genomic, laboratory, and clinical data to identify response patterns or toxicity risks. Practical value depends on representative datasets, transparent validation, regulatory alignment, cybersecurity, and clinician oversight. AI should therefore be implemented as a decision-support capability rather than a substitute for prospective evidence or medical judgment.

Regional Insights: Uneven Access Meets Expanding Scientific Capacity

North America combines advanced oncology infrastructure, active clinical research, and established diagnostic capabilities, while access and affordability remain important considerations. Europe benefits from strong academic networks and regulatory coordination, although reimbursement and national health-system decisions can differ. Asia-Pacific is supported by major research and manufacturing ecosystems, with substantial variation in access across economies. Latin America continues to expand specialized care while facing infrastructure and affordability constraints. The Middle East is investing in advanced healthcare capacity, whereas Africa has pronounced differences in diagnostic availability, specialist coverage, and treatment access across countries.

Group Insights: Alliances Influence Regulation, Research, and Access

ASEAN cooperation is relevant to harmonized regulatory processes, supply resilience, and cross-border clinical research. BRICS members bring substantial scientific, manufacturing, and patient-population capabilities but differ in health-system capacity and regulatory practice. The European Union benefits from shared scientific and regulatory structures while national reimbursement remains distinct. G7 countries contribute advanced biomedical research, sophisticated care systems, and influential standards. GCC members are strengthening tertiary-care infrastructure and regional coordination. NATO countries can support preparedness, secure supply chains, and collaborative biomedical research, although the group is not a uniform healthcare or reimbursement market.

Country Insights: Diverse Capabilities Shape Immunotherapy Adoption

The United States and Canada combine strong research capacity with extensive specialist networks, while affordability and access vary by payer and region. Germany, France, Italy, Spain, and the United Kingdom have mature clinical systems, with differences in health-technology assessment, reimbursement, and implementation. China, Japan, South Korea, India, and Australia contribute growing research, manufacturing, diagnostic, and specialist-care capabilities, alongside varied approval and access pathways. Brazil and Mexico serve as important Latin American healthcare markets but face regional disparities in specialist services and treatment availability. Russia maintains scientific and clinical capabilities, while access, procurement, and international operating conditions require careful assessment.

Priorities for Leaders: Build Evidence, Access, and Operational Resilience

Industry leaders should align development programs with validated biomarkers, clinically meaningful endpoints, and real-world evidence plans that address durability and quality of life. Investment in companion diagnostics, adverse-event management, decentralized support services, and clinician education can improve appropriate use. Cell and gene-based programs require robust chain-of-identity controls, specialized manufacturing, and contingency planning. Organizations should also establish responsible AI governance, protect sensitive health data, engage regulators and payers early, and design access strategies that reflect differences in infrastructure, reimbursement, and patient needs across geographies.

Research Methodology: Evidence-Based Assessment of the Immunotherapy Landscape

This executive summary uses a structured assessment of immunotherapy-drug modalities, clinical development practices, biomarker and diagnostic requirements, manufacturing considerations, healthcare-system conditions, and regional access factors. Insights are synthesized from publicly verifiable scientific literature, regulatory materials, clinical-trial records, health-system publications, and authoritative institutional sources. Regional, group, and country observations are comparative and qualitative; they do not constitute market estimates, forecasts, market shares, or financial projections.

Conclusion: Durable Progress Depends on Precision and Access

Immunotherapy drugs continue to advance through better biological understanding, more precise patient selection, innovative treatment formats, and increasingly integrated data. The central challenge is translating scientific progress into safe, durable, and equitable care. Leaders that combine rigorous evidence generation with diagnostic readiness, resilient operations, responsible AI, and locally appropriate access strategies will be better positioned to support sustainable clinical adoption across diverse healthcare environments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Immunotherapy Drugs Market, by Therapy Type
7.1. Introduction
7.2. Adoptive Cell Therapy
7.2.1. Car-T Therapy
7.2.2. Nk Cell Therapy
7.2.3. Tcr-T Therapy
7.3. Cancer Vaccines
7.3.1. Dendritic Cell Vaccines
7.3.2. Dna Vaccines
7.3.3. Peptide Vaccines
7.4. Checkpoint Inhibitors
7.4.1. Ctla-4 Inhibitors
7.4.2. Pd-1 Inhibitors
7.4.3. Pd-L1 Inhibitors
7.5. Cytokines
7.5.1. Colony Stimulating Factors
7.5.2. Interferons
7.5.3. Interleukins
7.6. Oncolytic Virus Therapy
7.6.1. Adenovirus Based
7.6.2. Herpesvirus Based
7.6.3. Reovirus Based
8. Immunotherapy Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Intratumoral
8.3. Intravenous
8.4. Subcutaneous
9. Immunotherapy Drugs Market, by Mechanism Of Action
9.1. Introduction
9.2. Active Immunotherapy
9.3. Passive Immunotherapy
10. Immunotherapy Drugs Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Oncology Clinics
10.4. Specialized Centers
11. Immunotherapy Drugs Market, by Indication
11.1. Introduction
11.2. Blood Cancer
11.2.1. Acute Lymphoblastic Leukemia
11.2.2. Acute Myeloid Leukemia
11.2.3. Chronic Lymphocytic Leukemia
11.2.4. Lymphoma
11.3. Breast Cancer
11.3.1. Hormone Receptor Positive
11.3.2. Triple Negative
11.4. Lung Cancer
11.4.1. NonSmallCell Lung Cancer
11.4.2. SmallCell Lung Cancer
11.5. Melanoma
11.5.1. Cutaneous Melanoma
11.5.2. Uveal Melanoma
12. Immunotherapy Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Immunotherapy Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Immunotherapy Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Affimed N.V.
16.3. AstraZeneca PLC
16.4. Atara Biotherapeutics, Inc.
16.5. Biogen Inc.
16.6. Bristol Myers Squibb Company
16.7. CARsgen Therapeutics Holdings Limited
16.8. Celldex Therapeutics, Inc.
16.9. Cipla Limited
16.10. Dr. Reddy’s Laboratories Limited
16.11. ElevateBio, LLC
16.12. Gilead Sciences, Inc.
16.13. GSK plc
16.14. Johnson & Johnson
16.15. Merck & Co., Inc.
16.16. Novartis AG
16.17. Pfizer Inc.
16.18. Regeneron Pharmaceuticals, Inc.
16.19. Roche Holding AG
16.20. Samyang Holdings Corporation
16.21. Sanofi SA
16.22. Takeda Pharmaceutical Company Limited
16.23. Teva Pharmaceutical Industries Ltd.
16.24. Turnstone Biologics Corp.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Immunotherapy Drugs Market, Years Considered for the Study
FIGURE 2. Global Immunotherapy Drugs Market, Research Design
FIGURE 3. Global Immunotherapy Drugs Market, Research Framework
FIGURE 4. Global Immunotherapy Drugs Market, Data Triangulation
FIGURE 5. Global Immunotherapy Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Immunotherapy Drugs Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Immunotherapy Drugs Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Immunotherapy Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Immunotherapy Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Immunotherapy Drugs Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 11. Global Immunotherapy Drugs Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Immunotherapy Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Immunotherapy Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Immunotherapy Drugs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 15. Global Immunotherapy Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Immunotherapy Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Immunotherapy Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Immunotherapy Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Immunotherapy Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Immunotherapy Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Immunotherapy Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Immunotherapy Drugs Market Segmentation & Coverage
TABLE 2. Global Immunotherapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Adoptive Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Adoptive Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Adoptive Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Car-T Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Car-T Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Car-T Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Nk Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Nk Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Nk Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Tcr-T Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Tcr-T Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Tcr-T Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Dendritic Cell Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Dendritic Cell Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Dendritic Cell Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Dna Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Dna Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Dna Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Peptide Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Peptide Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Peptide Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Checkpoint Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Checkpoint Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Checkpoint Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ctla-4 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ctla-4 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ctla-4 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Pd-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Pd-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Pd-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Pd-L1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Pd-L1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Pd-L1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Cytokines Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Cytokines Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Cytokines Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Colony Stimulating Factors Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Colony Stimulating Factors Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Colony Stimulating Factors Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Interferons Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Interferons Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Interferons Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Interleukins Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Interleukins Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Interleukins Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Oncolytic Virus Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Oncolytic Virus Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Oncolytic Virus Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Adenovirus Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Adenovirus Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Adenovirus Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Herpesvirus Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Herpesvirus Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Herpesvirus Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Reovirus Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Reovirus Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Reovirus Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 65. Global Intratumoral Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Intratumoral Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Intratumoral Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 75. Global Active Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Active Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Active Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Passive Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Passive Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Passive Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 82. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Specialized Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Specialized Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Specialized Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 92. Global Blood Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Blood Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Blood Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Acute Lymphoblastic Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Acute Lymphoblastic Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Acute Lymphoblastic Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Acute Myeloid Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Acute Myeloid Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Acute Myeloid Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Chronic Lymphocytic Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Chronic Lymphocytic Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Chronic Lymphocytic Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Hormone Receptor Positive Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Hormone Receptor Positive Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Hormone Receptor Positive Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Triple Negative Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Triple Negative Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Triple Negative Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global NonSmallCell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global NonSmallCell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global NonSmallCell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global SmallCell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global SmallCell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global SmallCell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Cutaneous Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Cutaneous Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Cutaneous Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Uveal Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Uveal Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Uveal Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 148. Asia-Pacific Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 149. Asia-Pacific Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 150. North America Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. North America Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 152. North America Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 153. North America Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 154. North America Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 155. North America Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 156. North America Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 157. North America Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. North America Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 159. North America Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. North America Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. North America Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 162. North America Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 163. North America Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 164. North America Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 165. Latin America Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 166. Latin America Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 167. Latin America Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 168. Latin America Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 169. Latin America Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 170. Latin America Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 171. Latin America Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 172. Latin America Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 173. Latin America Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 174. Latin America Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. Latin America Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 176. Latin America Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 177. Latin America Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 178. Latin America Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 179. Latin America Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 180. Europe Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Europe Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 182. Europe Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 183. Europe Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 184. Europe Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 185. Europe Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 186. Europe Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 187. Europe Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. Europe Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 189. Europe Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Europe Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. Europe Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 192. Europe Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 193. Europe Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 194. Europe Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 195. Middle East Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 196. Middle East Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 197. Middle East Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 198. Middle East Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 199. Middle East Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 200. Middle East Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 201. Middle East Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 202. Middle East Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 203. Middle East Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 204. Middle East Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Middle East Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 206. Middle East Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 207. Middle East Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 208. Middle East Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 209. Middle East Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 210. Africa Immunotherapy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 211. Africa Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 212. Africa Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 213. Africa Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 214. Africa Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 215. Africa Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 216. Africa Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 217. Africa Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 218. Africa Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 219. Africa Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Africa Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 221. Africa Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 222. Africa Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 223. Africa Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 224. Africa Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 225. Global Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 226. ASEAN Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 227. ASEAN Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 228. ASEAN Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 229. ASEAN Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 230. ASEAN Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 231. ASEAN Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 232. ASEAN Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 233. ASEAN Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 234. ASEAN Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 235. ASEAN Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. ASEAN Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. ASEAN Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 238. ASEAN Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 239. ASEAN Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 240. ASEAN Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 241. GCC Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. GCC Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 243. GCC Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 244. GCC Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 245. GCC Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 246. GCC Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 247. GCC Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 248. GCC Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 249. GCC Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 250. GCC Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. GCC Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 252. GCC Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 253. GCC Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 254. GCC Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 255. GCC Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 256. European Union Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 257. European Union Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 258. European Union Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 259. European Union Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 260. European Union Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 261. European Union Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 262. European Union Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 263. European Union Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 264. European Union Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 265. European Union Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. European Union Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. European Union Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 268. European Union Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 269. European Union Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 270. European Union Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 271. BRICS Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 272. BRICS Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 273. BRICS Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 274. BRICS Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 275. BRICS Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 276. BRICS Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 277. BRICS Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 278. BRICS Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 279. BRICS Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 280. BRICS Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. BRICS Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 282. BRICS Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 283. BRICS Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 284. BRICS Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 285. BRICS Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 286. G7 Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 287. G7 Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 288. G7 Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 289. G7 Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 290. G7 Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 291. G7 Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 292. G7 Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 293. G7 Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 294. G7 Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 295. G7 Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. G7 Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 297. G7 Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 298. G7 Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 299. G7 Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 300. G7 Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 301. NATO Immunotherapy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 302. NATO Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 303. NATO Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 304. NATO Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 305. NATO Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 306. NATO Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 307. NATO Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 308. NATO Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 309. NATO Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 310. NATO Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. NATO Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 312. NATO Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 313. NATO Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 314. NATO Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 315. NATO Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 316. Global Immunotherapy Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 317. United States Immunotherapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 318. United States Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 319. United States Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 320. United States Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 321. United States Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 322. United States Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 323. United States Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 324. United States Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 325. United States Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 326. United States Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. United States Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 328. United States Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 329. United States Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 330. United States Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 331. United States Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 332. Canada Immunotherapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 333. Canada Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 334. Canada Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 335. Canada Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 336. Canada Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 337. Canada Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 338. Canada Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 339. Canada Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 340. Canada Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 341. Canada Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 342. Canada Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 343. Canada Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 344. Canada Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 345. Canada Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 346. Canada Immunotherapy Drugs Market Size, by Melanoma, 2017-2032 (USD Million)
TABLE 347. Mexico Immunotherapy Drugs Market Size, 2017-2032 (USD Million)
TABLE 348. Mexico Immunotherapy Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 349. Mexico Immunotherapy Drugs Market Size, by Adoptive Cell Therapy, 2017-2032 (USD Million)
TABLE 350. Mexico Immunotherapy Drugs Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 351. Mexico Immunotherapy Drugs Market Size, by Checkpoint Inhibitors, 2017-2032 (USD Million)
TABLE 352. Mexico Immunotherapy Drugs Market Size, by Cytokines, 2017-2032 (USD Million)
TABLE 353. Mexico Immunotherapy Drugs Market Size, by Oncolytic Virus Therapy, 2017-2032 (USD Million)
TABLE 354. Mexico Immunotherapy Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 355. Mexico Immunotherapy Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 356. Mexico Immunotherapy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 357. Mexico Immunotherapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 358. Mexico Immunotherapy Drugs Market Size, by Blood Cancer, 2017-2032 (USD Million)
TABLE 359. Mexico Immunotherapy Drugs Market Size, by Breast Cancer, 2017-2032 (USD Million)
TABLE 360. Mexico Immunotherapy Drugs Market Size, by Lung Cancer, 2017-2032 (USD Million)
TABLE 36

Companies Mentioned

  • AbbVie Inc.
  • Affimed N.V.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited
  • Celldex Therapeutics, Inc.
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • ElevateBio, LLC
  • Gilead Sciences, Inc.
  • GSK plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samyang Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Turnstone Biologics Corp.

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Cancer Immunotherapy - Global Strategic Business Report - Product Image

Cancer Immunotherapy - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Drug Pipelines
  • 150 Pages
  • Global
From

About the Immunotherapy Market

Immunotherapy is a type of treatment used to treat immune disorders, such as allergies, asthma, and autoimmune diseases. It works by stimulating the body's own immune system to fight off disease-causing agents. Immunotherapy drugs are designed to target specific parts of the immune system, such as T-cells, B-cells, and cytokines. These drugs can be used to treat a variety of conditions, including cancer, HIV/AIDS, and rheumatoid arthritis. Immunotherapy drugs are typically administered through injections, infusions, or oral medications. They can also be used in combination with other treatments, such as chemotherapy or radiation therapy. The goal of immunotherapy is to reduce the severity of symptoms and improve the patient's quality of life. The immunotherapy market is a rapidly growing sector of the pharmaceutical industry. Companies in this market are focused on developing new treatments and therapies to treat immune disorders. Some of the major players in this market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.